Serum concentrations of cefotaxime and its metabolite desacetyl-cefotaxime in infants and children during continuous infusion

Infection

Volumn 36, Issue 5, 2008, Pages 415-420

  Bertels, R A ^a   Semmekrot, B A ^a   Gerrits, G P ^a   Mouton, J W ^a  

^a CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEFOTAXIME; DEACETYLCEFOTAXIME;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; BLOOD SAMPLING; CHILD; CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG EXCRETION; DRUG INFUSION; DRUG METABOLISM; FEMALE; GLOMERULUS FILTRATION RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIVER METABOLISM; MAJOR CLINICAL STUDY; MALE; NEWBORN; TREATMENT DURATION; URINARY EXCRETION;

ADOLESCENT; ANTI-BACTERIAL AGENTS; CEFOTAXIME; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE;

EID: 56549131197     PISSN: 03008126     EISSN: None     Source Type: Journal    
DOI: 10.1007/s15010-008-7274-1     Document Type: Article

References (29)

1. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10quiz 11-12.
2. Mouton JW, Vinks AA: Is continuous infusion of beta-lactam antibiotics worthwhile? Efficacy and pharmacokinetic considerations. J Antimicrob Chemother 1996; 38: 5-15.
3. Kasiakou SK, Sermaides GJ, Michalopoulos A, Soteriades ES, Falagas ME: Continuous versus intermittent intravenous administration of antibiotics: a meta-analysis of randomised controlled trials. Lancet Infect Dis 2005; 5: 581-589.
4. Mouton JW, Vinks AA: Continuous infusion of beta-lactams. Curr Opin Crit Care 2007; 13: 598-606.
5. Wise R, Wills PJ, Andrews JM, Bedford KA: Activity of the cefotaxime (HR756) desacetyl metabolite compared with those of cefotaxime and other cephalosporins. Antimicrob Agents Chemother 1980; 17: 84-86.
6. de Louvois J, Mulhall A, Hurley R: The safety and pharmacokinetics of cefotaxime in the treatment of neonates. Pediatr Pharmacol (NY) 1982; 2: 275-284.
7. Kearns GL, Young RA, Jacobs RF: Cefotaxime dosage in infants and children. Pharmacokinetic and clinical rationale for an extended dosage interval. Clin Pharmacokinet 1992; 22: 284-297.
8. Dulaney Lopez AM, Rodriguez JC, Lopez-Samblas AM, Estes KS: Limiting cefotaxime pediatric dosing to adult standards: a pharmacokinetic simulation study. Int J Clin Pharmacol Ther 1999; 37: 269-274.
9. McCracken GH Jr, Threlkeld NE, Thomas ML: Pharmacokinetics of cefotaxime in newborn infants. Antimicrob Agents Chemother 1982; 21: 683-684.
10. Baird-Lambert J, Doyle PE, Thomas D, Cvejic M, Buchanan N: Pharmacokinetics of cefotaxime in neonates. J Antimicrob Chemother 1984; 13: 471-477.
11. Jacobs RF, Kearns GL: Cefotaxime pharmacokinetics and treatment of meningitis in neonates. Infection 1989; 17: 338-342.
12. Kearns GL, Jacobs RF, Thomas BR, Darville TL, Trang JM: Cefotaxime and desacetylcefotaxime pharmacokinetics in very low birth weight neonates. J Pediatr 1989; 114: 461-467.
13. Goldwater PN: Cefotaxime and ceftriaxone cerebrospinal fluid levels during treatment of bacterial meningitis in children. Int J Antimicrob Agents 2005; 26: 408-411.
14. Sato Y: Pharmacokinetics of antibiotics in neonates. Acta Paediatr Jpn 1997; 39: 124-131.
15. Lassman HB, Coombes JD: Metabolism of cefotaxime: a review. Diagn Microbiol Infect Dis 1984; 2: 3S-12S.
16. Coombes JD: Metabolism of cefotaxime in animals and humans. Rev Infect Dis 1982; 4: S325-332.
17. Schwartz GJ, Feld LG, Langford DJ: A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984; 104: 849-854.
18. Lecaillon JB, Rouan MC, Souppart C, Febvre N, Juge F: Determination of cefsulodin, cefotiam, cephalexin, cefotaxime, desacetyl-cefotaxime, cefuroxime and cefroxadin in plasma and urine by high-performance liquid chromatography. J Chromatogr 1982; 228: 257-267.
19. Buijk SE, Gyssens IC, Mouton JW, Metselaar HJ, Groenland TH, Verbrugh HA, Bruining HA: Perioperative pharmacokinetics of cefotaxime in serum and bile during continuous and intermittent infusion in liver transplant patients. J Antimicrob Chemother 2004; 54: 199-205.
20. Gouyon JB, Pechinot A, Safran C, Chretien P, Sandre D, Kazmierczak A: Pharmacokinetics of cefotaxime in preterm infants. Dev Pharmacol Ther 1990; 14: 29-34.
21. Blake MJ, Castro L, Leeder JS, Kearns GL: Ontogeny of drug metabolizing enzymes in the neonate. Semin Fetal Neonatal Med 2005; 10: 123-138.
22. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE: Developmental pharmacology - drug disposition, action, and therapy in infants and children. N Engl J Med 2003; 349: 1157-1167.
23. van den Anker JN, Schoemaker RC, Hop WC, van der Heijden BJ, Weber A, Sauer PJ, Neijens HJ, de Groot R: Ceftazidime pharmacokinetics in preterm infants: effects of renal function and gestational age. Clin Pharmacol Ther 1995; 58: 650-659.
24. Nakazawa S, Sato H, Hirama Y, Chikaoka H: [Study of intravenous cefotaxime therapy in neonates]. Jpn J Antibiot 1982; 35: 1761-1766.
25. Nishimura T, Takashima T, Hiromatsu K, Tabuki K: [Studies on the pharmacokinetics of cefotaxime in neonates]. Jpn J Antibiot 1982; 35: 1793-1800.
26. Marik PE: Aminoglycoside volume of distribution and illness severity in critically ill septic patients. Anaesth Intensive Care 1993; 21: 172-173.
27. Roberts JA, Lipman J: Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet 2006; 45: 755-773.
28. Crooks J, White LO, Burville LJ, Speidel BD, Reeves DS: Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in neonates. J Antimicrob Chemother 1984; 14: 97-101.
29. White LO, Holt HA, Reeves DS, Bywater MJ, Bax RP. Separation and assay of cefotaxime (HR-756) and its metabolites in serum, urine, and bile. Curr Chemother Infect Dis: Proc 1980; 153-154.